147 related articles for article (PubMed ID: 10688119)
1. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1.
Evans SM; Kachur AV; Shiue CY; Hustinx R; Jenkins WT; Shive GG; Karp JS; Alavi A; Lord EM; Dolbier WR; Koch CJ
J Nucl Med; 2000 Feb; 41(2):327-36. PubMed ID: 10688119
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of new hypoxia markers EF1 and [18F]-EF1.
Kachur AV; Dolbier WR; Evans SM; Shiue CY; Shiue GG; Skov KA; Baird IR; James BR; Li AR; Roche A; Koch CJ
Appl Radiat Isot; 1999 Dec; 51(6):643-50. PubMed ID: 10581679
[TBL] [Abstract][Full Text] [Related]
5. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
Jenkins WT; Evans SM; Koch CJ
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1005-17. PubMed ID: 10705024
[TBL] [Abstract][Full Text] [Related]
7. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
[TBL] [Abstract][Full Text] [Related]
10. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
[TBL] [Abstract][Full Text] [Related]
11. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
Lord EM; Harwell L; Koch CJ
Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
[TBL] [Abstract][Full Text] [Related]
12. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
[TBL] [Abstract][Full Text] [Related]
13. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
Bading JR; Alauddin MM; Fissekis JD; Shahinian AH; Joung J; Spector T; Conti PS
J Nucl Med; 2000 Oct; 41(10):1714-24. PubMed ID: 11038003
[TBL] [Abstract][Full Text] [Related]
14. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
[TBL] [Abstract][Full Text] [Related]
15. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
[TBL] [Abstract][Full Text] [Related]
16. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy.
Busk M; Horsman MR; Jakobsen S; Keiding S; van der Kogel AJ; Bussink J; Overgaard J
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1202-12. PubMed ID: 18313528
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
